Sentences with phrase «in women with ovarian cancer»

In their research, scientists at Rutgers created animal models that closely resemble the cancerous tumors found in women with ovarian cancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratory mice.

«This study provided encouraging preliminary results for the use of RT in women with ovarian cancer.»

It is now in a phase II clinical trial in women with ovarian cancer, which almost always has p53 mutations.

Not exact matches

Yet 20 % of women diagnosed with lung cancer each year — about 21,000 in 2010, roughly the same number as new cases of ovarian cancer — never smoked.

For women who choose to breastfeed there are lower risks associated with breast and ovarian cancer, less chance of hip fractures and osteoporosis in later life, and the added benefit that it helps with getting back to their pre-baby weight.

Recent research demonstrates that lactating women have an earlier return to prepregnant weight, 41 delayed resumption of ovulation with increased child spacing,42 - 44 improved bone remineralization postpartum45 with reduction in hip fractures in the postmenopausal period, 46 and reduced risk of ovarian cancer47 and premenopausal breast cancer.48

Part of my mission is to share information about ovarian cancer with women in order to help them understand the risk factors, symptoms and precautions to promote early detection and reduce ovarian cancer related deaths.

For that reason, the American Cancer Society recommends annual MRI screenings only in women with a strong family history of breast or ovarian cCancer Society recommends annual MRI screenings only in women with a strong family history of breast or ovarian cancercancer.

In reality, it turns out that many women with high levels of CA 125 do not have ovarian cancer, and, conversely, many women with cancer do not have high levels of CA 125.

Thousands of women are living with ovarian cancer in Canada.

Among postmenopausal women, the women with the highest quartile of HEI - 2010 scores were 43 percent less likely to be diagnosed with ovarian cancer, and the women with the highest quartile AHEI - 2010 scores were 51 percent less likely to be diagnosed with ovarian cancer than the women in the lowest quartile.

Qin said that among all African - American women in the study, those with the highest adherence to an AHEI - 2010 diet were 34 percent less likely to be diagnosed with ovarian cancer than women with the lowest AHEI - 2010 adherence.

Because ovarian cancer is relatively rare, occurring in approximately one out of every 2,500 women, a test with only 99 percent specificity would result in false - positive diagnoses for 25 women, leading to unnecessary and risky surgeries and procedures.

In order to assess whether an improved diet could reduce the risk of ovarian cancer in African - American women, Qin analyzed the diets of 415 women with ovarian cancer and 629 control patients, using data from the African - American Cancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United StateIn order to assess whether an improved diet could reduce the risk of ovarian cancer in African - American women, Qin analyzed the diets of 415 women with ovarian cancer and 629 control patients, using data from the African - American Cancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United Scancer in African - American women, Qin analyzed the diets of 415 women with ovarian cancer and 629 control patients, using data from the African - American Cancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United Statein African - American women, Qin analyzed the diets of 415 women with ovarian cancer and 629 control patients, using data from the African - American Cancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United Scancer and 629 control patients, using data from the African - American Cancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United SCancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United Scancer in African - American women in 11 sites in the United Statein African - American women in 11 sites in the United Statein 11 sites in the United Statein the United States.

The study, which compared each model's success in Caucasian women with those of Asian descent (Chinese, Japanese, Filipino, Korean and Vietnamese), also raised important questions about the effect of race on cancer development: When Caucasian and Asian patients with similar family histories of breast and ovarian cancer were compared, the Asian women had higher rates of genetic mutation, although the rates of these cancers for Asians have traditionally been lower.

It is estimated that 2,700 Canadian women will be diagnosed with ovarian cancer in 2014 and that 1,750 Canadian women will die from the disease, according to Ovarian Cancer ovarian cancer in 2014 and that 1,750 Canadian women will die from the disease, according to Ovarian Cancer Ccancer in 2014 and that 1,750 Canadian women will die from the disease, according to Ovarian Cancer Ovarian Cancer CCancer Canada.

Women with a family history of two or more immediate family members (mother, sister, daughter) with breast or ovarian cancer or with a positive genetic test for mutations in the BRCA1 or BRCA2 genes may be advised to consider having both breasts removed, because they are at high risk of a new cancer developing in the other breast.

TRINOVA - 1 was a randomized prospective phase III clinical trial that added trebananib or placebo to standard chemotherapy (weekly paclitaxel) among 919 women with recurrent ovarian cancer patient from 179 sites in 32 countries.

Those in the heaviest group, women with a BMI over 28, had only 52 percent the ovarian cancer incidence of recruits in the leanest group, those with a BMI of 23 and under.

An analysis of mutations in the BRCA1 and BRCA2 genes reveals that women with breast cancer and women with ovarian cancer harbored mutations in different regions of the genes.

They also found differences in the types of bacteria in the upper reproductive tracts of women with and without epithelial ovarian cancer.

In the Hereditary Ovarian Cancer Clinical Study, researchers from Canada, the United States, Poland, Norway, Austria, France, and Italy identified women with BRCA mutations from an international registry, 5,787 of whom completed questionnaires about their reproductive history, surgical history (including preventive oophorectomy and mastectomy), and hormone use.

During a median follow - up of 5 years, 426 women were diagnosed with breast cancer, 109 with ovarian cancer, and 245 with contralateral breast cancer (cancer in the breast opposite to one previously diagnosed with cancer).

«Ovarian follicles used to preserve fertility: Technique could be beneficial for women with cancer; study in mice produced live births.»

Dr. Narod, who is also a Tier 1 Canada Research Chair in Breast Cancer, recommends that doctors should consider adopting a standard model of care for all women diagnosed with advanced - stage ovarian cCancer, recommends that doctors should consider adopting a standard model of care for all women diagnosed with advanced - stage ovarian cancercancer:

In 80 women with the mutation that he has studied, 80 per cent developed breast cancer and 20 per cent ovarian cancer.

«One in five women with ovarian cancer does not undergo surgery, study reveals: Results show survival benefit of surgery for patients regardless of age or advanced disease, and point to barriers to cancer care delivery.»

«For decades, women have been treated with a combination of treatment options, resulting in poor prognosis for most women with advanced - stage ovarian cancer, but there are many survivors as well,» said Dr. Narod, senior scientist at Women's College Research Instiwomen have been treated with a combination of treatment options, resulting in poor prognosis for most women with advanced - stage ovarian cancer, but there are many survivors as well,» said Dr. Narod, senior scientist at Women's College Research Instiwomen with advanced - stage ovarian cancer, but there are many survivors as well,» said Dr. Narod, senior scientist at Women's College Research InstiWomen's College Research Institute.

More than 80 percent of women with advanced stage high - grade serous ovarian cancer experience relapses even after repeated surgeries and multiple rounds of chemotherapy, and this effective new approach to treat the disease could be a major step forward in preventing cancer from returning.

In 2014, the FDA approved bevacizumab with chemotherapies for the treatment of women with platinum - resistant, recurrent ovarian cancer.

When Lisbeth Ceriani, a 43 - year - old Massachusetts woman, was diagnosed with breast cancer last year, her doctors recommended that she undergo genetic testing to see if she carried mutations in the BRCA1 and BRCA2 genes that increase risk of breast and ovarian cancers.

«The results from our study are not practice - changing at this time; however, our findings suggest that using a longitudinal (or change over time) screening strategy may be beneficial in post-menopausal women with an average risk of developing ovarian cancer,» said Dr. Lu.

For women with ovarian cancer, a particularly deadly form of gynecologic cancer, even improvements in treatment outcomes have been elusive.

She estimates that about 50 percent of women with ovarian cancer have tumors with this type of tumor and would qualify for the trial, which needs about $ 2 million in philanthropic funding before it could begin.

This month, two studies in the JCI investigated the mechanisms underlying the treatment resistance associated with some BRCA1 mutations, and the findings provide information that may help predict which treatments will be effective in women with breast and ovarian cancer.

Tamara Minko, professor in the Ernest Mario School of Pharmacy, and Lorna Rodriguez, professor of obstetrics, gynecology and reproductive sciences at Robert Wood Johnson Medical School, say because there is not a good screening method for ovarian cancer, most women with the disease are not diagnosed until after it has metastasized to other organs and surgery and chemotherapy are not as effective.

The need for better access to fertility preservation has become more pressing in recent years for two reasons: first, the improved rates of survival in young women and girls diagnosed with cancer; and second, improvements in the techniques of freezing eggs and ovarian tissue to restore fertility.

Olaparib was licensed in December for women with ovarian cancer and inherited BRCA mutations, but the new research suggests it could also benefit men with genomic faults within their tumours.

Women with endometriosis have a 1.5 percent lifetime chance of developing ovarian cancer compared with 1 percent in the general female population.

Analysing certain genes in these cells enabled them to detect 33 per cent of ovarian cancers and 81 per cent of endometrial cancers in Pap test specimens collected from 627 women already diagnosed with these diseases.

Now, however, a team led by Merajver and another headed by Ellen Solomon and John Trowsdale of the Imperial Cancer Research Fund in London say that they have both found damaged copies of BRCA1 in ovarian tumours from women with no family history of cancer (Nature Genetics, vol 9, p 343 andCancer Research Fund in London say that they have both found damaged copies of BRCA1 in ovarian tumours from women with no family history of cancer (Nature Genetics, vol 9, p 343 andcancer (Nature Genetics, vol 9, p 343 and 439).

Women with Stage III ovarian cancer given a combination of intravenous and intraperitoneal chemotherapy following surgical debulking of tumor had a median survival nearly 16 months longer than women who received IV chemotherapy alone, according to a study published conducted by the Gynecologic Oncology Group (GOG), a National Cancer Institute - supported research network, in the January 5, 2006 issue of the New England Journal of MediWomen with Stage III ovarian cancer given a combination of intravenous and intraperitoneal chemotherapy following surgical debulking of tumor had a median survival nearly 16 months longer than women who received IV chemotherapy alone, according to a study published conducted by the Gynecologic Oncology Group (GOG), a National Cancer Institute - supported research network, in the January 5, 2006 issue of the New England Journal of Medcancer given a combination of intravenous and intraperitoneal chemotherapy following surgical debulking of tumor had a median survival nearly 16 months longer than women who received IV chemotherapy alone, according to a study published conducted by the Gynecologic Oncology Group (GOG), a National Cancer Institute - supported research network, in the January 5, 2006 issue of the New England Journal of Mediwomen who received IV chemotherapy alone, according to a study published conducted by the Gynecologic Oncology Group (GOG), a National Cancer Institute - supported research network, in the January 5, 2006 issue of the New England Journal of MedCancer Institute - supported research network, in the January 5, 2006 issue of the New England Journal of Medicine.

Carriers of BRCA2 mutations composed a smaller sample set; in particular, the number of women with BRCA2 - associated ovarian cancers was relatively small.

Dinah Bazer, a 69 - year old woman from Brooklyn, New York, who participated in the NYU study, was diagnosed with ovarian cancer in 2010.

Around 18 women in every 1,000 develop ovarian cancer, but this risk increases to around 58 women in every 1,000 for women with a fault in the BRIP1 gene.

Each year in the UK around 7,100 women are diagnosed with ovarian cancer and more than 4,200 women die from the disease.

Therefore, new treatment modalities and paradigms are needed in order to significantly improve the prognosis of women diagnosed with epithelial ovarian cancer.

I am a board - certified gynecologic oncologist who specializes in the surgical treatment of women with known or suspected ovarian and endometrial cancers.

Each year nearly 22,280 women in the United States will be diagnosed with ovarian cancer, and 14,240 will die.

The agent was previously approved in December 2016 for the treatment of ovarian cancer specifically associated with BRCA mutations, in women who had received at least two prior chemotherapy regimens.